CA1248094A - Agent antitumoraux, tels que la daunorubicine a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux - Google Patents

Agent antitumoraux, tels que la daunorubicine a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux

Info

Publication number
CA1248094A
CA1248094A CA000422514A CA422514A CA1248094A CA 1248094 A CA1248094 A CA 1248094A CA 000422514 A CA000422514 A CA 000422514A CA 422514 A CA422514 A CA 422514A CA 1248094 A CA1248094 A CA 1248094A
Authority
CA
Canada
Prior art keywords
glutaraldehyde
agent
active agent
tumor
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000422514A
Other languages
English (en)
French (fr)
Inventor
Edgar H. Relyveld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of CA1248094A publication Critical patent/CA1248094A/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000422514A 1982-02-26 1983-02-28 Agent antitumoraux, tels que la daunorubicine a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux Expired CA1248094A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8203272A FR2522269A1 (fr) 1982-02-26 1982-02-26 Agents antitumoraux, tels que la daunorubicine, a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux
FR8203272 1982-02-26

Publications (1)

Publication Number Publication Date
CA1248094A true CA1248094A (fr) 1989-01-03

Family

ID=9271408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000422514A Expired CA1248094A (fr) 1982-02-26 1983-02-28 Agent antitumoraux, tels que la daunorubicine a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux

Country Status (7)

Country Link
US (1) US4625019A ( )
EP (1) EP0088022B1 ( )
JP (1) JPS59500273A ( )
CA (1) CA1248094A ( )
DE (1) DE3374411D1 ( )
FR (1) FR2522269A1 ( )
WO (1) WO1983002946A1 ( )

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2551442B1 (fr) * 1983-09-05 1987-04-30 Centre Nat Rech Scient Nouveaux derives furaniques, leur preparation et leur application
EP0213811A3 (en) * 1985-08-16 1987-09-09 Johnson Matthey, Inc., Bateriocin-targeted compounds for cancer therapy
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
CN1069099C (zh) * 1995-09-29 2001-08-01 科学技术振兴事业团 阿霉素的二聚物和三聚物
US6020316A (en) * 1997-09-25 2000-02-01 Lanks; Karl W. Glutaraldehyde modified chemotherapeutic agents and methods of use thereof
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
CA2361421A1 (en) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
JP2002063917A (ja) * 2000-08-18 2002-02-28 Sony Corp 電気化学デバイス及びその使用方法
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
WO2006050368A2 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
GB2017125B (en) * 1978-03-17 1982-07-21 California Inst Of Techn Polyglutaraldehyde synthesis and protein bonding substrates
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
SE7813460L (sv) * 1978-03-27 1979-09-28 Mca Disco Vision Videoskivspelare
US4202967A (en) * 1978-10-02 1980-05-13 Sri International N,N-pentamethylene derivatives of daunomycin and adriamycin
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning

Also Published As

Publication number Publication date
EP0088022B1 (fr) 1987-11-11
FR2522269A1 (fr) 1983-09-02
FR2522269B1 ( ) 1985-03-01
EP0088022A1 (fr) 1983-09-07
JPS59500273A (ja) 1984-02-23
DE3374411D1 (en) 1987-12-17
WO1983002946A1 (en) 1983-09-01
US4625019A (en) 1986-11-25

Similar Documents

Publication Publication Date Title
CA1248094A (fr) Agent antitumoraux, tels que la daunorubicine a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux
EP0089880B1 (fr) Nouveaux conjugués associant, par liaison covalente, une enzyme et un anticorps, et associations médicamenteuses utilisant lesdits conjugués
Kravtzoff et al. Erythrocytes as carriers for L‐asparaginase. Methodological and mouse in‐vivo studies
EP0769967B1 (fr) Conjugues comprenant un agent antitumoral et leur utilisation
FR3017299A1 (fr) Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
CH647411A5 (fr) Procede de preparation de produits cytotoxiques.
EP0352147A2 (fr) Utilisation de la Naringine, de la Naringénine ou leurs dérivés pour faire une composition pharmaceutique anticancéreuse
EP0080401A1 (fr) Nouveaux médicaments anticancéreux pour le traitement des leucémies T constitués de la chaine A de la ricine et d'un anticorps monoclonal spécifique
Yu et al. A ferroptosis-inducing and leukemic cell-targeting drug nanocarrier formed by redox-responsive cysteine polymer for acute myeloid leukemia therapy
US20200010575A1 (en) Semi-synthetic biopolymers for use in treating proliferative disorders
KR930003116B1 (ko) 종양의 광역학적 치료용 조성물
FR2522001A1 (fr) Polysaccharides, leur preparation et compositions therapeutiques contenant ces produits
FR2547500A1 (fr) Preparation pharmaceutique pour ulcere du tube digestif
FR2550944A1 (fr) Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
EP0172045B1 (fr) Glycoprotéines antitumorales, modifiées sur leurs motifs glucidiques, procédé d'obtention
EP1558630A2 (fr) Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
EP0192002B1 (fr) Immunotoxines à longue durée d'action comportant un constituant glycopeptique inactivant les ribosomes modifié sur ses motifs polysaccharidiques
EP0234151B1 (fr) Glycoprotéines modifiées par oxydation et formation de base de Schiff, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine
CA2352134A1 (fr) Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide
FR2649321A1 (fr) Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
EP0162781B1 (fr) Conjugués associant par liaison covalente un ionophore carboxylique monovalent et une macromolécule, leur utilisation comme agents potentialisateurs des immunotoxines et les ionophores activés intermédiaires
FR2547731A1 (fr) Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
CH663033A5 (fr) Substance-melange dite ''spf-100'' et procede pour sa preparation.
KR20170085663A (ko) 난노클로롭시스를 이용한 클로로필 a 제조방법
EP0279757A1 (fr) Ensemble ou kit pour utilisation comme agent pour la destruction sélective de cellules transformées

Legal Events

Date Code Title Description
MKEX Expiry